Marilyn White

Researchers have uncovered an upper limit in tumor burden after which there is a lower probability of successfully downstaging patients with hepatocellular carcinoma for liver transplantation.

Multidisciplinary tumor boards led to higher utilization of guideline-recommended curative therapies, which was associated with improved overall survival for patients with early-stage hepatocellular carcinoma.

Treatment with direct-acting antiviral therapy did not increase the risk of developing hepatocellular carcinoma in patients with hepatitis C virus (HCV) infection.

A new system for gauging the probability for hepatocellular carcinoma recurrence following liver transplant surgery has proved successful.

Following on their impressive success in the treatment of several other tumor types, immune-based therapies are being studied in clinical trials for hepatocellular carcinoma and are showing promising signals of efficacy.

Similar recurrence-free survival was demonstrated with radiofrequency ablation using percutaneous and laparoscopic methods for patients with hepatocellular carcinoma who were eligible for ablation.

The use of immunotherapy as a treatment for cancer is progressively increasing with a flood of recent approvals for immune checkpoint inhibitors directed against CTLA-4 and PD-1.

Efforts are under way to further evaluate the effects of regorafenib on sorafenib-resistant HCC cells, including the role of suppressing the ERK signaling pathway.